Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SynCore Biotechnology Co.,Ltd (4192.TWO)
Yilan City, TW
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.56% | +1.01% | +2.04% | -8.26% | -24.39% | -19.68% | -31.03% | -70.10% | -88.99% | -85.48% | -95.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+15.9% ★ Q1'26: +13.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-84,315.6% Q1'26: +5.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-148.8% Q1'26: -91.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-174.5% Q1'26: -219.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-56.6% Q1'26: -58.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-99.9% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: -0.41× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Muh-Hwan Su | President & GM | 4M | — |
| Hui-Hung Wang | General Manager | 2M | male |
| Wen-Hsin Huang | Vice President & Head of Drug Development Department | 1M | male |
| Chih-Wen Lee | Founder & Chairman of the Board | 1M | male |
| Chia-Hao Liang | Head of Financial & General Affairs Department and Accounting Manager | — | male |
| Ruey-Wen Lin | Head of Quality Assurance Department | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4192.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
